The demand for weight-loss medications like Ozempic has led to global shortages, creating opportunities for counterfeit drugs. The introduction of generic Liraglutide may impact pricing but not immediately. Companies like Hims & Hers face challenges as supply increases. The EU urges prioritizing patients in need amid drug shortages.
Shares of telehealth company Hims & Hers are under pressure as scrutiny of its weight loss business intensifies https://t.co/axPvVAqbDZ
Piggybacking off the $HIMS conversation last night with a new short report out today, I'll address the points in a post below. Seems to be a lot of broad-based targeting with $HIMS in it as opposed to $HIMS specifically https://t.co/FWJAsL09O5
$HIMS okay so is the hims short report legit or no down 10%… https://t.co/eDGUMMzPqv
don’t normally like staying involved in names that get short seller drama but I’m buying some HIMS here. I understand taking profit (stock is up huge) but if you’re selling because of the points raised by this short report (like “it’s easy to get a prescription” and “if the… https://t.co/RMENyCItbc
$NVO New weight loss drug may be better than Ozempic — here’s how https://t.co/BVV3fk2aiA
The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs. https://t.co/RbEEA6GCJS
$HIMS short report- the stock is up 3-4x yoy- it's an easy ST target now given where new money now buying in
Knock-off Ozempic not looking so lucrative this morning $HIMS
The EU’s drug regulator urged countries to clamp down on cosmetic use of powerful drugs for weight loss and diabetes, saying that patients who need the medicines most must get priority as shortages continue. https://t.co/ughHTuWL3u via @business
$HIMS -15% in pre-mkt trading as @hntrbrkmedia's report continues to gain traction. https://t.co/UWYrDIUC75
$HIMS down as much as 7% in pre https://t.co/qEnz6EfWnf
Enter the activist short on $HIMS. Note the report has a journalistic slant, with efforts to contact the company (no response) and comments from the compounding pharmacy in question. (And ICYMI: My take on this from @streetbeatspros a month ago: https://t.co/JgtJ9eQSPu) https://t.co/NetNo0U9qx
I sold plenty around 25 which was my target but hopefully if this newbie short report provide a big dip will Re-add some sales! $HIMS https://t.co/jjPjelv02R
$HIMS - Hims & Hers Selling GLP-1 Injection That's Not FDA Approved, From Shady Supplier — And Won't Make You Talk to a Doctor to Get It https://t.co/wBxTPqivPe
EU urges clampdown on cosmetic misuse of Novo's Ozempic amid worsening drug shortages for diabetics. https://t.co/lIFVswRPyu
$NVO $LLY STATNEWS: https://t.co/3Dsv9K75RI
$NVO $LLY EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics https://t.co/hZZlEvuvPD
Anticipated Pricing for Generic Liraglutide: $469.60 for the 2-pack $704.40 for the 3-pack This pricing is atrocious given the competitive marketplace. https://t.co/fCItmf5Ccu
Anticipated Pricing for Generic Liraglutide: $469.60 for the 2-pack $704.40 for the 3-pack For a drug that is as lousy as Liraglutide 1.8 mg, this pricing is a robbery. I haven’t put a patient on Victoza in a decade. There are many better alternatives. https://t.co/fCItmf54mW
The EU’s drug regulator urged countries to clamp down on cosmetic use of powerful drugs for weight loss and diabetes, saying that patients who need the medicines most must get priority as shortages continue. https://t.co/AFAxz5ljN8
Can you please expand on this, @david_wainer: “ $HIMS & Hers claims that even when drugs such as #semaglutide are removed from the FDA shortage list, it could keep selling them.” $NVO $LLY @AndrewDudum @AppleHelix @realtahiramin @wbfeldman @AcquiredFM https://t.co/qsDnU58w0Z
"America’s insatiable demand for weight-loss medications is minting vast fortunes—and not just for the makers of GLP-1 drugs such as Ozempic." - @david_wainer https://t.co/2iTAzuGJE5 $LLY $HIMS
Generic Liraglutide Is Here – Will It Make Any Difference? - ConscienHealth https://t.co/cPNSgUCPTY greed and inertia in this market are good descriptions
Heard on the Street: Once Eli Lilly and Novo Nordisk increase the supply of weight-loss medications, companies such as Hims & Hers may find it trickier to sell compounded versions of the drugs https://t.co/X4T9xXWBjo
Generic Liraglutide Is Here – Will It Make Any Difference? - ConscienHealth https://t.co/9ZDjqHBTdd
Generic liraglutide is here. Will it lead to a moderation in pricing of diabetes and #ObesityMedicines? Maybe, but not right away. Here's why. https://t.co/6iDAsF57Dg
Generic #Liraglutide Is Here – Will It Make Any Difference? - @ConscienHealth https://t.co/970AOEUnLy
With everyone from obesity patients to celebrities demanding Ozempic and other drugs like it, the frenzy has sparked global shortages—opening the door to life-threatening fakes. https://t.co/ayBsjfOEDv